The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, which was approved by the FDA in April, as well as its range of recombinant clotting factor replacement products.

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a week.

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi,

Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency approved Hympavzi as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX